Poland· PL-100040350

Macmiror complex

A nifuratel product containing nifuratelum + nystatinum, registered in Poland by Polichem S.A.. The same ATC class is registered in 2 of our 19 countries.

ATC G01AX05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedMacmiror complexATCG01AX05REGISTER NO.PL-100040350PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Nifuratel is registered in 2 of 19 countries.

Countries holding a registration under ATC G01AX05 (nifuratel), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 2 of them publish a price we can compare per daily dose

Nifuratel · ATC G01AX05

2 / 19 countries

  • Czechiaprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Nifuratelum + Nystatinum
Manufacturer
Polichem S.A.
Country
Poland (PL)
ATC code
G01AX05
ATC class
Nifuratel
Defined daily dose
0.6 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990032419

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Nifuratel in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nifuratel products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

  • Bulgaria · Макмирор Комплекс
  • Czechia · Macmiror Complex
  • Croatia · Macmiror Complex
  • Hungary · Macmiror Complex
  • Italy · Inimur Complex, Macmiror Complex
  • Lithuania · Macmiror Complex
  • Latvia · Livormac
  • Portugal · Dafnegil
  • Romania · Macmiror Complex, Macmirorcomplex
  • Slovakia · Macmiror Complex, Macmiror Complex 500

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/08fd2627-fec2-4ef7-9de9-b9ecdb95d95c
GET /v1/drugs/08fd2627-fec2-4ef7-9de9-b9ecdb95d95c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Maść dopochwowa",
  "source": "urpl",
  "strength": "(100 mg + 40000 j.m.)/g",
  "packaging": "05909990032419 ¦ Rp ¦ 6193\n1 op. 30 g",
  "substance": "Nifuratelum 10 g + Nystatinum 4 mln. j.m.",
  "common_name": "Nifuratelum + Nystatinum",
  "pl_product_id": "100040350",
  "pozwolenie_nr": "00324",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about nifuratel.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.